Literature DB >> 618781

Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy.

M Husain, R N Alsever, J P Lock, W F George, F H Katz.   

Abstract

We describe 3 patients with metastatic medullary carcinoma of the thyroid who were treated with doxorubicin hydrochloride (Adriamycin). Serum calcitonin was measured before and after doxorubicin therapy. Doxorubicin failed to arrest the progression of the disease in any of the patients. Although serum calcitonin levels dropped in 1 patient during therapy, they remained markedly elevated in all 3 patients. From the present series it appears that medullary thyroid carcinoma often does not have a response to doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618781     DOI: 10.1159/000178893

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  10 in total

Review 1.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

2.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection.

Authors:  J F Moley; M K DeBenedetti
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

3.  Chemotherapy of thyroid carcinoma.

Authors:  S Ahuja; H Ernst
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

4.  Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.

Authors:  D G Wang; W H Liu; C F Johnston; J M Sloan; K D Buchanan
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

Review 5.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

Review 6.  Medullary thyroid cancer: medical management and follow-up.

Authors:  Amber Traugott; Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2005-07

7.  Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Authors:  Serena Giunti; Alessandro Antonelli; Andrea Amorosi; Libero Santarpia
Journal:  Int J Endocrinol       Date:  2013-02-21       Impact factor: 3.257

8.  Medullary thyroid carcinoma.

Authors:  Jeffrey F Moley
Journal:  Curr Treat Options Oncol       Date:  2003-08

9.  Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).

Authors:  M Schlumberger; N Abdelmoumene; M J Delisle; J E Couette
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

Review 10.  Targeted Therapy for Medullary Thyroid Cancer: A Review.

Authors:  S R Priya; Chandra Shekhar Dravid; Raghunadharao Digumarti; Mitali Dandekar
Journal:  Front Oncol       Date:  2017-10-06       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.